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Ex vivo expanded erythroblasts (EBs) may serve as advanced transfusion products provided that lodgment occurs in the
macrophage-niche of the marrow permitting maturation. EBs expanded from adult and cord blood expressed the receptors
(CXCR4, VLA-4, and P-selectin ligand 1) necessary for interaction with macrophages. However, 4-days following transfusion
to intact NOD/SCID/IL2Rγnull mice, CD235apos EBs were observed inside CD235aneg splenic cells suggesting that they underwent
phagocytosis. When splenectomized and intact NOD/SCID/IL2Rγnull mice were transfused using retrovirally labeled human EBs,
human cells were visualized by bioluminescence imaging only in splenectomized animals. Four days after injection, human
CD235apos cells were detected in marrow and liver of splenectomized mice but only in spleen of controls. Human CD235apos
erythrocytes in blood remained low in all cases. These studies establish splenectomized NOD/SCID/IL2Rγnull mice as a suitable
model for tracking and quantiﬁcation of human EBs in vivo.
1.Introduction
Culture conditions capable of generating ex vivo human
erythroblasts (EBs) in numbers suﬃcient for transfusion
have been established by several investigators (reviewed
in [1]) increasing the likelihood that these cells could
serve as alternative transfusion products [2]. The preclinical
evaluation of these products includes testing the in vivo
potency of ex vivo generated cells in animal models [3].
The development of animal models to assess the potency of
human EBs generated exvivorequiresabetterunderstanding
of the interactions between human EBs and the murine
microenvironment and identiﬁcation of animal manipula-
tions which may favor lodgment of these cells in the marrow.
In vivo, EBs mature in specialized areas of the mar-
row in close proximity to macrophages which favors both
hemoglobinization, by facilitating iron uptake, and enu-
cleation [4, 5]. Following enucleation, reticulocytes lose
their association with the macrophage and egress into the
blood stream. EBs interact with the macrophages through
the surface adhesion receptors CXCR4 (CD184), P-selectin
ligand1 (PSGL1, CD162), and VLA-4 (CD49d, α4 integrin)
which recognize CXCL12 (also known as SDF1), P-selectin
and VCAM1, respectively, on the surface of the macrophage
[4]. Under steady-state conditions, few EBs egress from the
marrow and these are usually cleared by macrophages in
the spleen [6]. Smears of cultured human EBs often contain
macrophages surrounded by clusters of EBs indicating
that cultured EBs are capable of interacting with human
macrophages derived from blood. However, the adhesion
receptor proﬁle of ex vivo generated EBs and the eﬃciency2 Stem Cells International
of the interaction of these cells with murine macrophages are
presently unknown.
Neildez-Nguyen et al. have reported that human carbox-
yﬂuorescein diacetate succinimidyl ester- (CFSE-) labeled
EBs expanded ex vivo from CD34pos cells isolated from
cord blood diﬀerentiate into red blood cells when trans-
fused to NOD/SCID mice [7]. The transfusion protocol
included coadministration of exogenous human erythropoi-
etin (EPO) and intraperitoneal administration of packed
human red cells to block the reticuloendothelial system
(leading to transient functional splenectomy). Initially,
human CFSEpos cells were detected in bone marrow, liver,
spleen and lung of the transfused animals and, beginning
at day 4, also in peripheral blood. However, these exper-
iments have been viewed with skepticism because human
CD34pos cells engrafted in immunodeﬁcient mice typically
generate robust levels of lymphoid and myeloid cells but
barely detectable numbers of erythroid cells [8]. These
data have been interpreted as evidence that the murine
microenvironment is not permissive for maturation of EBs.
Although the molecular structures of human and murine
EPO are very similar, it has been suggested that murine
EPO may fail to support optimal maturation of human
EBs because it does not induce dimerization after binding
to the human receptor [9]. This hypothesis was indirectly
supported by Nicolini et al who reported that treatment
with human EPO after transplantation greatly increases the
generation of human erythroid cells when human CD34pos
cells are injected into immunodeﬁcient mice [10]. However,
the relative contribution of administration of human EPO
and packed human red cells to the success of the animal
model for human transfusion developed by Neildez-Nguyen
et al. [7] has not been clariﬁed as yet.
The aim of our study was to test whether ex vivo
generatedEBsexpresstheadhesionreceptorproﬁlenecessary
to complete their maturation in vivo and whether inhibition
of the interaction between ex vivo generated EBs and splenic
macrophages will permit establishment of an in vivo model
for functional evaluation of ex vivo expanded human EBs.
2.MaterialsandMethods
2.1. Human Subjects. Low volume cord blood units (CB)
were obtained from the New York Blood Center (New York,
NY, USA). Peripheral blood (PB) was collected from normal
adult donors at the transfusion center of “La Sapienza”
University (Rome, Italy). Both specimens were collected
according to guidelines established by institutional ethical
committees and provided as deidentiﬁed samples.
2.2. Mice. 12-week-old female NOD/SCID/IL2Rγnull mice
were purchased from Jackson laboratory and housed in the
animal facility of Memorial Sloan-Kettering Cancer Center.
All murine studies were performed according to institutional
animal care and use committee approved protocols.
2.3. Cell Preparation. Mononuclear cells (MNCs) from CB
andABwereobtainedbycentrifugationoverFicoll-Hypaque
(Amersham Pharmacia Biotec, Uppsala, Sweden). CD34pos
cells from CB were separated using the Human Cord
Blood CD34 Selection Kit (STEMCELL Technologies Inc,
Vancouver, BC, Canada), as described by the manufacturer.
2.4. Expansion of Human Erythroblasts. CD34pos cells and
MNC (5 × 104 and 106 cells/mL, resp.) were cultured under
human erythroid massive ampliﬁcation (HEMA) conditions
in a proliferative phase stimulated with stem cell factor
(SCF, 10ng/mL, R&D System, Minneapolis, MN, USA),
erythropoietin (EPO, 5U/mL, Epogen, Amgen, Thousand
Oaks, CA, USA) and interleukin 3 (IL-3, 1ng/mL, Biosource,
San Jose, CA, USA), dexamethasone and estradiol (both at
10
−6M, Sigma, St. Louis, MO, USA) up to 10 days and
subsequently in a diﬀerentiative phase stimulated with EPO
(5U/mL), insulin (10ng/mL, Calbiochem, La Jolla, CA,
USA),andFeSO4 (10
−6M,Sigma) upto 4days,aspreviously
described [11, 12].
2.5. Colony Forming Assay. The colony forming ability of
sorted cells was evaluated in standard semisolid methylcel-
lulose cultures (40%, Fluka Biochemika) stimulated with
SCF (10ng/mL), IL-3 (10ng/mL), granulocyte-macrophage
colony-stimulating factor (GM-CSF, 10ng/mL), granulocyte
colony-stimulating factor (G-CSF, 100ng/mL) and EPO
(5U/mL). The cultures were incubated at 37◦Ci naf u l l y
humidiﬁed 5% pCO2 atmosphere and scored after 2 days for
colony forming unit erythroid (CFU-E) and after 8 days for
burst forming unit erythroid (BFU-E) and colony forming
unit granulocyte-macrophages (CFU-GM) colonies.
2.6. Cell Viability and Phenotypic Analysis. Cell numbers and
viabilitywereassessedbymicroscopicevaluationaftertrypan
blue (Boston Bioproducts, Ashland, MA, USA) staining.
Erythroid cells were identiﬁed using standard morphological
criteria by visual examination of cytocentrifuged cell prepa-
rations (Cytospin 3, Shandon, Astmoor, England) stained
with May-Gr¨ unwald-Giemsa (Fisher Scientiﬁc, Pittsburg,
PA, USA) using the Axioscope light microscope equipped
with a Coolsnap video camera (Zeiss, Oberkochen, Ger-
many). For ﬂow cytometric analyses, cells were suspended
in Ca2+/Mg2+-free phosphate-buﬀered saline, supplemented
with 1% BSA, stained with either phycoerythrin- (PE-)
conjugated CD36 (antithrombospondin receptor) [13],
-CD184 (CXCR4), -CD162 (PSLG1), -CD49d (VLA-4), or
allophycocyanin- (APC-) conjugated CD235a (anti-glyco-
phorin A), pan hematopoietic human- (FITC-) conjugated
CD45 or appropriate isotype controls (all from Becton
Dickinson Biosciences, Franklin Lakes, NJ, USA). For GFP
determinations, autoﬂuorescence of untreated cells was
analysed as negative control. Fluorescence was analyzed with
the FACS Canto (Becton Dickinson Biosciences) equipped
with three air-cooled and solid-state lasers (488nm, 633nm
and 407nm). Dead cells were excluded by propidium iodide
(PI, 5μg/mL, Sigma) staining.
2.7. Fluorescence Labelling of Human EBs. CFSE Labeling.
EBs obtained at day 11 of HEMA cultures were stained withStem Cells International 3
CFSE (10μM, Invitrogen, Carlsbad, CA, USA) as described
[14] and cultured for 24 additional hrs under HEMA
conditions. Retrovirally mediated labeling.C BC D 3 4 pos cells
were cultured for 3 days in X-VIVO 10 media (Lonza Walk-
ersville, Walkersville, MD, USA) containing thrombopoietin
(TPO, 100ng/mL), SCF (100ng/mL), Flt3 Ligand (Flt3L,
100ng/mL), IL-3 (20ng/mL), and the PG-13 retroviral
producersupernatant[15,16]whichcontainsthemembrane
anchored form of the Gaussia luciferase enzyme (extGLuc)
[16] was added twice 24hrs apart. The transfected CD34pos
cells were then cultured under HEMA conditions for 6
additional days. An aliquot of nontransduced CD34pos cells
from the same isolation was cultured in parallel under
HEMA condition as control.
2.8. Transfusion Protocol. Two protocols were investi-
gated. In the ﬁrst experiment (See Supplementary Fig-
ure 1 in Supplementary Material available online at doi:
10.4061/2011/673752), 2 NOD/SCID/IL2Rγnull mice were
injected via the tail vein with 25 × 106 CFSE-labeled
EBs. Twenty-four hrs prior to injection, mice were bled
(500μL) to increase endogenous EPO levels. In the second
experiment (Supplementalry Figure 2), intact and splenec-
tomized NOD/SCID/IL2Rγnull mice (4 mice per group)
were used. NOD/SCID/IL2Rγnull mice were anaesthetized
with isoﬂurane (Baxter, Deerﬁeld, USA) and splenectomized
after double ligation of the splenic artery and vein [17].
The muscle, peritoneum, and skin were closed in sepa-
rate layers using sterile 5–0 absorbable suture. Intact and
splenectomised mice were transfused via the tail vein with
25 × 106 retrovirally labeled EBs together with human EPO
(20U/mouse). Twenty four hours earlier, mice had been
bled (500μL). In both experiments, mice receiving culture
media only served as negative controls and all the mice were
sacriﬁced 4-5 days following transfusion for further analyses.
2.9. Immunocytochemistry. Smears of single cell suspensions
from femur, spleen, and liver and cultured EBs prepared
by cytocentrifugation (Shandon, Astmoor, England) were
ﬁxed with paraformaldehyde (3.7%, Electron Microscopy
ScienceHatﬁeld, PA, USA) for 30min and rinsed 2 times
with double distilled water. Smears were incubated with
an antihuman glycophorin A antibody (CD235a, Abcam,
Cambridge, MA, USA) and the immunoreaction detected
with the avidin-biotin immunoperoxidase system (Vectas-
tain Elite ABC Kit; Vector Laboratories, Burlingame, CA) on
slides counterstained with hematoxylin-eosin, as described
by the manufacturer. Aliquots of injected EBs and smears
from media-treated mice were used as positive and neg-
ative controls, respectively. Histological observations were
carried out using a ZEISS AXIOSKOPE light microscope
(Jena, Germany) equipped with a Coolsnap Videocamera.
Enumeration of human CD235apos cells was performed by
two separate investigators in a blinded fashion.
2.10. Bioluminescence Imaging. Bioluminescence was detect-
ed using a Xenogen IVIS Imaging System (Xenogen) as pre-
viously described [18]. Imaging was performed 24–48 hrs
following intravenous injection of coelenterazine (250μg)
(Nanolight Technology) via the tail vein. Dorsal and ventral
images of the animals were acquired with acquisition times
in the range of 1 to 3min. Field of view of 15, 20, or
25cm with low, medium, or high binning in an open ﬁlter
was utilized to maximize signal intensity and sensitivity. We
obtained acquisition of image datasets and measurements
of signal intensity through region of interest (ROI) analysis
using Living Image software (Xenogen). Normalized images
are displayed on each dataset according to color intensity.
2.11. Statistical Analyses. Results are expressed as mean
(±SD) of at least three replicate experiments unless stated
otherwise. Statistical analysis was performed by Anova using
the computer software Origin 5.0 for Windows (Microcal
Software, Inc., Northampton, MA, USA).
3. Results
3.1. Cord Blood MNC Generate Greater Numbers of Less
Mature Erythroid Cells Than Adult Blood MNC under HEMA
Conditions. Our group has previously identiﬁed a culture
strategy for massive production of EBs ex vivo from both
CB and AB MNC deﬁned as human erythroid massive
ampliﬁcation (HEMA) culture [11]. Under these culture
conditions, in the experiments included in this paper, AB
MNC generated EBs with an FI = 15 while the number of
EBs generated by CB MNC was 3-times greater (FI = 40
Figure 1).
By CD36/CD235a proﬁling, EBs generated under HEMA
conditions may be separated into 4 classes of progressively
more mature cells represented by CD36high/CD235aneg (class
I, gate R1) and CD36highCD235alow (class II, gate R2)
cells, which contain colony-forming unit-erythroid (CFU-
E) and pro-EBs, and CD36highCD235ahigh (class III, gate
R3) and CD36lowCD235ahigh cells (class IV, gate R4), which
contain basophilic-polychromatic and orthochromatic EBs,
respectively(SupplementalFigure3).BFU-E-andCFU-GM-
derived colonies are not detectable in cells generated in
HEMA culture from day 8 on (data not shown). At day 10
of HEMA culture, a signiﬁcant proportion of EBs generated
in cultures of AB and CB MNC are represented by immature
c l a s sIa n dc l a s sI IE B s( 3 8a n d7 8 % ,r e s p . )( F i g u r e1 and
Table 1). Exposure of Day 10EBs derived from both AB and
CB to EPO alone for 4 days increased the proportion of
mature class III and IV EBs up to 52–70%. CB-derived EBs
contained a lower fraction of mature cells than AB-derived
E B sb o t hi nH E M Ac u l t u r ea n dw h e nc u l t u r e dw i t hE P O
alone (Figure 1 and Table 1).
Macrophage islands surrounded by 6–9EBs were com-
monly detected in smears of both AB and CB derived
EBs beginning at day 7 and up to day 10 of HEMA
culture (Figure 1(c)). The frequency of these islands on the
smears was correlated with the frequency of nonerythroid
cells which had survived in culture (data not shown). The
randomnaturethemacrophagesinHEMAcultureprevented
quantiﬁcation of this phenomenon. Further studies in which
cultured EBs will be exposed to monocytes puriﬁed from4 Stem Cells International
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Figure 1:MNCfromABandCBgenerategreatnumbersofEBsunderHEMAconditions.(a)Cellnumber(asFoldIncrease,FI,withrespect
to day 0), (b) maturation proﬁle (cytoﬂuorimetric analysis on the basis of the expression of CD36 and CD235a), and (c) representative
morphology (by May-Grunwald staining) of EBs generated in HEMA culture seeded with MNC from either CB or AB. The ability of CB and
AB EBs obtained at day 10 to proceed along the maturation pathway after 4 days of culture in the presence of EPO only is also compared (b).
The ﬂow cytometric proﬁle used to deﬁne EBs maturation is presented in Supplemental Figure 3. The ﬂow charts are representative of those
obtained in at least three independent experiments with MNC from diﬀerent CB or AB donors. The numbers in the quadrants present the
frequency of EBs in the gates R1 to R4. Frequencies obtained in multiple experiments are presented as mean (±SD) in Table 1.
Table 1: Frequency of EBs divided according to their maturation proﬁle at day 10 of HEMA culture seeded with AB and CB MNC and after
4 days of additional culture in EPO alone to induce maturation. The gates used to deﬁne the 4 maturation classes used in this study are
described in Supplemental Figure 3.
Maturation classes AB MNC CB MNC
Day 10 (%)∗ Day 4 + EPO (%) Day 10 (%) Day 4 + EPO (%)
Class I (CD36highCD235aneg)1 7 .0 ±6.21 .6 ±0.65 3 .8 ±8.91 1 .9 ±4.8
Class II (CD36highCD235alow)2 1 .7 ±4.19 .7 ±1.12 1 .5 ±6.51 0 .6 ±4.5
Class III (CD36highCD235ahigh)4 9 .2 ±2.45 5 .1 ±7.49 .1 ±4.64 9 .5 ±6.4
Class IV (CD36lowCD235ahigh)1 .2 ±1.11 5 .8 ±4.40 .2 ±0.61 .7 ±1.1
∗Percentages were calculated with respect to the total cell population present in culture (EBs and non EBs).
human blood, marrow, and spleen are required to deﬁne the
interaction between these cell populations in vitro.
3.2. Dynamic Pattern of Adhesion Receptor Proﬁling during
the Maturation of AB- and CB-Derived EBs in Culture. The
expression patterns of CXCR4, PSLG1, and VLA-4 on EBs
obtained from AB and CB at day 10 of HEMA and induced
to mature for 4 days in cultures containing EPO alone is
presented in Figures 2, 3, and Supplemental Figure 4.
Expression of CXCR4 was barely detectable either in AB-
or CB-derived EBs at day 10 of culture, irrespective of the
stage of maturation (Figures 2 and 3). Exposure of these
cells to EPO alone rapidly (within 1 day) activated CXCR4
expression ﬁrst on immature cells (Class 1, R1) and then
by day 4 also on cells expressing a more mature phenotype
(Class 2 for AB EBs and Class 2 + 3 for CB EBs). The most
mature Class 4 EBs (both from AB and CB) never expressed
CXCR4 (Figures 2 and 3). The dynamic pattern of CXCR4
expression is visualized by the direct comparison of CD184
(CXCR4) and CD235a (glycophorin A) expression as AB
and CB EBs matured in EPO alone culture presented in
Supplemental Figure 4. Although similar patterns of CXCR4
expression were observed in EBs derived from AB and
CB, a greater percentage (30–80% versus 15–40%) of CB-
derived EBs expressed CXCR4 than AB EBs and the mean
ﬂuorescence intensity (MFI) was also greater for CB (range
1000–2500 versus 500–1000).
At day 10, both AB and CB derived EBs expressed high
levels of PSLG1 regardless of their maturation stage (80–
90% PSLG1pos cells with MFI in the range of 1000–4000)
(Figures 2 and 3). The expression of PSLG1 was conserved
when EBs were induced to mature with EPO alone for
4 days (Figures 2 and 3) although direct comparison of
PSLG1 expression against CD235a indicated an associationStem Cells International 5
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Figure 2: Adhesion receptor proﬁling during in vitro maturation of EBs expanded from AB (a) and CB (b). Three color ﬂow cytometry
analysis for CD36 and CD235a in combination with either CXCR4 (CD184), PSGL-1 (CD162), or VLA-4 (CD49d) of EBs obtained at day
10 of HEMA culture from AB and CB MNC (Prol 10) and at day 1 (Diﬀ Day 1) and 4 (Diﬀ Day 4) of maturation with EPO alone, as
indicated. EBs were divided into 4 maturation classes deﬁned by the levels of CD36 and CD235a expression identiﬁed by the gates R1 to R4
and corresponding to Class 1 to 4 (see Supplemental Figure 3 for further details).
between reduced expression of this receptor and maturation
which was particularly evident in the case of AB-derived EBs
(Supplemental Figure 4).
A great percentage (60–100%) of day 10EBs expressed
robust levels of VLA-4 (MFI in the range of 1000–3000
for AB EBs and 2000–6000 for CB EBs) regardless of their
maturation status. The frequency of VLA4pos EBs remained
high when the cells were induced to mature with EPO for
4 days, although in the case of AB EBs the levels of VLA4
expression per cell decreased with time in culture when
stimulated with TPO alone (Figures 2 and 4). The apparently
high maturation-independent pattern of VLA4 expression
in AB and CB EB was also observed by direct analyses of
VLA4/CD235a expression patterns (Supplemental Figure 4).6 Stem Cells International
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Figure 3: Time course of the frequency and MFI of CXCR4, PSL1, and VLA4 expression during in vitro maturation of EBs expanded from
adult and cord blood, as indicated. Values observed with EBs at diﬀerent stages of maturation are color coded: Class 1 (gate R1): light orange,
Class 2 (gate R2): red, Class 3 (gate R3): brown, and Class 4 (gate R4): black (see also Supplemental Figure 1). The results correspond to the
ﬂow charts presented in Figure 2.
Inconclusionday10EBsexpresslowlevelsofCXCR4but
robust levels of PSLG1 and VLA4. Induction of these cells to
mature by exposure to EPO alone rapidly activates CXCR4
expression but has modest or no eﬀect on the expression
of PSLG1 and VLA4, with the exception of a reduction in
the number of PSLG1pos class 2 and class 3 EBs observed in
culture of AB-derived cells.
3.3. Cell Fate of Ex Vivo Expanded CB EBs in NOD/SCID/
IL2Rγnull Mice. The greater levels of adhesion receptor
expression of CB EBs suggested that these cells might be
more able than AB EBs to establish the cellular interactions
necessary for maturation in vivo and therefore more suitable
for use in animal models to analyze cell fate following
transfusion. We chose the NOD/SCID/IL2Rγnull mouse as
the animal model for these experiments because it has been
shown to readily support engraftment of human CD34pos
hematopoietic stem cells and represents a superior, long-
lived model suitable for studies employing xenotransplanta-
tion strategies [20, 21].
In preliminary experiments, the fate of murine RFP-
labeled EBs derived from liver and transfused into syngeneic
thalassemic mice was determined. Murine RFP-labeled EBs
(30–150 × 106) transfused in unbled thalassemic mice
generated undetectable or barely detectable levels of red
cells. By contrast, when mice were bled 150 to 600μL2 4h r s
beforetransfusion,thesamenumbersofmurineRFP-labeled
EBs generated as many as 5 × 109-5 × 1010 red cells (A.R.
MigliaccioandP.Frenette,unpublishedobservations).These
results indicate that bleeding facilitates in vivo maturation
of transfused murine EBs, probably by increasing endoge-
nous EPO levels. On the basis of these data we decided
to bleed animals 24hr prior to transfusion with human
EBs.
In the initial three experiments, CFSE-labeled EBs
derivedfromCD34pos CBcellsafter11daysinHEMAculture
weretransfusedviathetailvein(25×106 EBspermouse)into
NOD/SCID/IL2Rγnull mice that were bled (500μL) the day
before (Supplemental Figure 3). Mice were sacriﬁced at day 4
after transfusion for detection of human CD235apos EBs andStem Cells International 7
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Figure 4: At day 4 after transfusion, human EBs are mostly detectable in spleen of NOD/SCID/IL2Rγnull mice. (a) Flow cytometric
analysis for human CD235a and CFSE expression of bone marrow and spleen cells from transfused and nontransfused (negative control)
NOD/SCID/IL2Rγnull mice. The results are representative of those obtained with 2 mice per group (see Table 2 for further details) and
are representative of those observed in three separate experiments. (b) Immunocytochemistry for human CD235a of cells from the spleen
of untransfused (top left panel) and transfused (lower panels) mice sacriﬁced 4 days after the human EBs transfusion, as indicated. Cells
from control mice (top left panel) are negative while cultured human EBs (top right panel) are all positive. In transfused mice, human
CD235apos cells (arrows) represented up to 18.2 ± 5.6% of total splenic cells. However, they were trapped inside larger CD235aneg cells,
probably macrophages of murine origin. Magniﬁcations 40x and 100x, as indicated.
Table 2: Frequency and total number of cells expressing the human CD235a in bone marrow and spleen of NOD/SCID/IL2Rγnull mice
transfused 4 days earlier with CFSE-labeled EBs. Both CFSE-positive and CFSE-negative human CD235apos cells were detected in the organs
of the animals after transfusion, an indication that some of the human Ebs had proliferated in vivo.
CSFE+CD235a+
(%)
CSFE−CD235a+
(%) CSFE++CSFE−CD235a+−control (%) Total no. of CD235+
cells/organ∗
BM
Control 0.3 0.34 0
Transfused mice (2 mice) 0.53–0.75 1.1–1.07 0.99–1.18 3.0–3.5 ×106
Spleen
Control 1.02 1.04 0
Transfused mice (2 mice) 3.34–5.75 1.3–1.6 2.57–5.29 2.6–5.3 ×106
The frequency of human CD235a+ cells was obtained after subtracting the background signal observed in untreated controls.
∗The total number of cells per organ was calculated assuming that a mouse contain 300 ×106 BM and 100 ×106 spleen cells [19].
at day 21 for the presence of human hematopoietic cells of all
lineages (CD45pos).
At day 4, FACS analyses revealed the presence of 0.99–
1.18%and2.57–5.29%ofCD235apos cells (both CFSEpos and
CFSEneg) in bone marrow and spleen, respectively, of the
transfused mice (Figure 4(a) and Table 2) .T h ep r e s e n c eo f
CFSEnegCD235apos cells indicated that some of the human
EBs had undergone proliferation in vivo during the 4 days
after transfusion. Assuming that the total number of cells
in bone marrow and spleen of a mouse is 300 × 106 cells
and ∼108 cells, respectively [19], it is calculated that the
bonemarrowandspleenofthetransfusedanimalscontained8 Stem Cells International
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Figure 5: Ex vivo expanded extGLuc+ EBs express high level of eGFP by FACS analyses. Maturation proﬁle and transfection eﬃciency
of nontransfected (as control, top panels) and transfected (bottom panels) EBs at day 9 of HEMA culture identiﬁed on the basis of
CD36/CD235a and eGFP expression (on the left) and on the basis of morphology (May-Grunwald staining, on the right), magniﬁcation
40x. The transfected EBs express great levels of eGFP. The transfection did not alter the morphology of the cells but slightly reduced the
expression of the CD235a probably due to interference with the GFP signal. At day 9, in transfected and control cultures the fold increase
was 48-fold and 325-fold, respectively, and the viability was 98% in both cases.
∼ 3.5 × 106 (1.7% of 3 × 108 cells) and 7 × 106 (6.8% of
108 cells) human EBs, respectively (Table 2). Therefore, the
majority of human EBs lodged in the spleen. Immunocyto-
chemical analyses for the expression of the human erythroid
CD235a marker conﬁrmed the presence of numerous (18%
of the total cell population) human CD235apos cells in the
spleen of the transfused animals (Figure 4(b)). However,
the CD235apos cells were trapped inside larger CD235aneg
cells, probably macrophages of murine origin. By day
18, very few (0.01–0.06%) human CD235apos cells were
detectable in the blood. By day 21, human CD45pos cells were
undetectable in marrow, spleen, and liver of the transfused
NOD/SCID/IL2Rγnull mice, conﬁrming the colony forming
data, which indicated that CB EBs expanded for 10 days
under HEMA conditions no longer contain hematopoietic
progenitorcells.TheseresultssuggestthathumanEBslodged
preferentially in the spleen where they were engulfed and
probably destroyed by macrophages.
To determine if splenectomy would facilitate lodgment
in the marrow, the fate of ex vivo expanded EBs trans-
fused to splenectomized and intact NOD/SCID/IL2Rγnull
mice was compared. Cell biodistribution was analyzed
by retroviral-mediated labeling with the external Gaussia
luciferase genes (extGLuc), using bioluminescence imaging,
and e green ﬂuorescent protein (eGFP) was used for ﬂow
cytometry determinations of CD34pos CB cells which were
then expanded under HEMA conditions (see [16]a n d
Supplemental Figure 2). The extGLuc enzyme is a newly
engineered Gaussia luciferase which contains the CD8 trans-
membrane domain at its carboxy terminus. The presence of
this domain allows membrane anchoring and cell surface
retention of extGLuc, signiﬁcantly enhancing the biolumi-
nescent signal [16].
The expansion potential of retrovirally transduced and
control CD34pos CB cells is compared in Figure 5.B yd a y9 ,
5 ×104 unmanipulated CD34pos CB cells generated 16 ×106
EBs (FI = 325-fold) while 5 × 106CD34pos CB cells which
had been cultured for 3 days under conditions permissive
for retroviral transduction (see Supplemental Figure 2)
generated 240 × 106 EBs (FI = 48), the great majority
of which (80%) expressed robust levels of eGFP (MFI >
5 × 104). The diﬀerence in FI between HEMA culture of
unmanipulated and retrovirally transduced CD34pos CB cells
was not associated with changes in death rates, as evaluated
by propidium iodide staining (data not shown) and may
be related to the likelihood of underestimations of the low
number of cells (5 × 104) used to initiate the cultures of un-
manipulated cells. By FACS analysis, the majority of CD36pos
EBs derived from retrovirally transduced CD34pos CB cells
didnotexpressCD235a.However,bymorphologicalanalysis
the maturation stage of these cells was comparable to that
of EBs derived from un-manipulated CB cells (Figure 5).Stem Cells International 9
We believe that lower expression of CD235a by the retro-
virally transduced EBs was a consequence of interference
between the ﬂuorescence signal of this antibody and that of
eGFP.
Aliquots (25 × 106) of retrovirally transduced EBs were
injected via the tail vein together with 20U of human EPO
in splenectomized and control NOD/SCID/IL2Rγnull mice
whichhadbeenbled(500μL)thedaybefore.Bioluminescent
imaging was performed 24 and 48hrs after transfusion.
Twenty-four hrs after transfusion, the extGLuc biolumines-
cent signal was virtually undetectable, other than at the site
of injection in intact mice (Figure 6). In contrast, signiﬁcant
levels of extGLuc signal were observed in legs and skull of
splenectomized mice, an indication that human EBs may
have homed to the BM. In these mice, signiﬁcant levels of
bioluminescent signal were also detected in the abdomen
(Figure 6). These data demonstrate that in the absence of the
spleen CB EBs lodge in marrow and liver.
Four days after transfusion, mice were sacriﬁced and the
presenceofhumanCD235apos cellsinbonemarrowandliver
of the transfused NOD/SCID/IL2Rγnull mice was analyzed
by FACS. In the case of intact mice, great numbers (∼15%
of the total cell population) of human CD235apos cells were
detected in spleen while human CD235pos cells in marrow
and liver were barely detectable. By contrast, in splenec-
tomized animals, great numbers of human CD235apos cells
were detectable in bone marrow (25%) and liver (7%)
(Figure 7). Interestingly these cells did not express CD36, an
indication that they had matured in vivo.H o w e v e r ,r e dc e l l s
inthebloodremainedlowbothinintactandsplenectomized
mice (data not shown).
These results indicate that the removal of the spleen
favors homing of human EBs to the bone marrow of NOD/
SCID/IL2Rγnull mice.
4. Discussion
An important issue for the quality and safety of cellular
products lies in the development of a surrogate assay for a
cell product that is as close as possible to the ﬁnal product
intended for therapeutic use. Short of a phase I clinical
study, the optimal evaluation of human cell products is
represented by preclinical studies performed in immuno-
deﬁcientmousemodels.Inourexperience,suchanapproach
can not only help validation studies and the establishment of
a potency assay, but also help guide the development of the
productionprocessitselfbydeﬁningoptimalcellpuriﬁcation
procedures, culture conditions, and scale-up systems. This
study focused on establishing a xenogeneic model to test
EBs expanded ex vivo under HEMA conditions as potential
transfusion products. The availability of such a model may
advance other areas of research by providing a single method
tocomparethefunctionalstatusofEBsderivedfromprimary
hematopoietic stem/progenitor cells with those derived from
other stem cells sources such as human embryonic stem cells
and induced pluripotent stem cells.
This study demonstrates that the maturation of ex vivo
generated CB- and AB-derived EBs is associated with a
dynamic pattern of adhesion receptor expression. At day
10–11 of HEMA culture, the majority of immature AB-
and CB-derived EBs expressed low levels of CXCR4 and
high levels of both VLA-4 and P-selectin ligand 1 (Figures
2 and 3). Once induced to mature by exposure to EPO
alone, these EBs rapidly (within 24hrs) activated expression
of CXCR4 while retaining expression of VLA-4 and down-
modulating expression of PSGL-1. By day 4 of maturation
culture, the majority of EBs had progressed to the mature
CD235ahighCD36high phenotype (Figure 1 and Table 1)a n d
had reduced expression of all the adhesion receptors.
Minor ontogenetic diﬀerences where observed since CB
EBs expressed greater levels of CXCR4, PSGL-1, and VLA4
and activated CXCR4 expression upon EPO exposure more
readily than AB EBs. While the adhesion receptor pattern
expressed by human erythroblasts maturing in vivo is not
known, these data are available in mice. Immature murine
E B so b t a i n e df r o mb o t hf e t a ll i v e ra n da d u l tb o n em a r r o w
e x p r e s sr o b u s tl e v e l so fC X C R 4 ,P S G L - 1a n dα4 integrins.
These cells lose PSGL-1 expression and retain CXCR4 and
VLA-4 expression with maturation [22, 23]. These high
levels of CXCR4 represent the major diﬀerence between the
pattern of adhesion receptors expressed by murine cells and
those expressed by ex vivo expanded human EBs. The low
levels of CXCR4 expression in human EBs generated in
HEMA and the fact that these cells rapidly, within 24hrs,
acquire CXCR4 expression upon exposure to EPO alone are
consistent with reports that CXCR4 expression is suppressed
by dexamethasone [24], one of the components of HEMA
culture [11]. On the other hand, the low levels of CXCR4
expression observed when human EBs mature (Class 4)
is expected since these cells are supposed to downregulate
expression of CXCR4, the major receptor involved in cell
retention in the marrow [25], as part of the process which
allows them to egress from the marrow [6].
A separate set of experiments evaluated the fate of
CFSE- or retrovirally-labeled CB-derived human EBs when
transfused in NOD/SCID/IL2Rγnull mice. Bleeding and/or
infusing the animals with human EPO to increase EPO
levels greatly increased the detection of human EBs in the
animals. By day 4 after transfusion, 1.5–5% of the cells in
BM and spleen, respectively, of the animals were positive for
human CD235pos by ﬂow cytometry (Figure 4(a)). However,
by immunohistochemistry, high numbers (18%) of cells
positive for human CD235a by immunohistochemistry were
detectableinthespleen(Figure4(b)).ThehumanCD235apos
cells, however, appeared trapped inside larger CD235a cells
suggesting that they had probably undergone phagocytosis
by murine macrophages. These results indicated that pref-
erential splenic lodgment and clearance of human EBs may
represent a barrier to the use of mouse models for functional
evaluation of human transfusion products.
CXCR4 plays a major role in cell lodgment and retention
in bone marrow [25] but is dispensable for cell homing
in spleen [17, 19]. We hypothesized that failure of human
CB EBs to lodge in bone marrow may be determined
by unbalanced expression of CXCR4 with respect to the
expression of other adhesion receptors, such as PSGL1,
VLA-4, and CD36 (CD36 speciﬁcally guide cell interaction
with the endothelial system [26]). Therefore, removal of10 Stem Cells International
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Figure 6: Signiﬁcant level of extGLuc signal is detectable in splenectomized mice 24hrs after transfusion. Bioluminescent imaging of
nonsplenectomized (left panels) and splenectomized (right panels) mice 24hrs after injection with extGLuc+EBs, as indicated. Dorsal and
ventral imaging is presented in the top and bottom panels, respectively. In intact mice, the bioluminescent signal was virtually undetectable
other than at the site of injection (the tail). In the splenectomized mice, signiﬁcant signal levels were observed in limbs (lower extremity),
skull (indicating marrow localization), and abdomen (indicating liver localization because the spleen had been removed). Arrows indicate
the positive signal. Data are representative of those observed with 4 mice per experimental point.
the spleen, by reducing cell interactions mediated by these
receptors, may favor lodgment in the marrow of EBs
expressing low levels of CXCR4. This hypothesis was tested
by comparing lodgment of human EBs in the bone marrow
of intact and splenectomized NOD/SCID/IL2Rγnull mice.
Bioimaging, followed by ﬂow cytometry analyses, indicated
that in the absence of the spleen retrovirally-labeled human
EBslodgeingreaternumbersinthemarrowofthetransfused
animals (Figure 6). These results indicate that removal of the
spleen greatly improves the survival of human EBs in mice.
However, although signs of in vivo maturation were detected
(detection in the marrow of cells positive for human CD235a
but negative for CD36), the numbers of human erythrocyte
detectedinthebloodofthetransfusedanimalsremainedlow.
Since CXCR4 expression was likely upregulation when
human EBs were transfused in vivo (the cells were no longer
exposed to DXM but exposed to human EPO), it is possible
that, in addition to splenectomy, lodgment of human EBs
in the marrow of the transfused animals may be improved
by experimental approaches designed to increase CXCR4
expression, such as short pretransfusion exposure to EPO in
vitro (Figures 2 and 3). Since cycling cells are known to have
inferior homing [27, 28], in addition to increasing CXCR4
expression, these pretreatments may also improve homing
by reducing the number of proliferating EBs. Indirect
proof that CXCR4 over-expression may facilitate homing of
human EBs in the marrow was recently obtained. Although
treatments with many chromatin modifying agents decreases
CXCR4 expression [29] the HDAC inhibitor valproic acid
(VPA) is well known for its ability to upregulate CXCR4
expression while downmodulating expression of α-integrins
and other adhesion receptors in several cell types [30, 31].
Recently Chaurasia et al. [32] have demonstrated that ex vivo
expanded EBs obtained from VPA-treated CB CD34pos cells
colonize, in addition to the spleen, the bone marrow when
transfused into NOD/SCID and NOD/SCID/IL2Rγnull mice
which had been functionally splenectomized by blocking the
reticuloendothelium system with intraperitoneal injectionStem Cells International 11
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Figure 7: By ﬂow cytometry of human CD36/CD235a expression, human CD235apos cells were detectable in marrow and liver of
splenectomized mice 4 days after transfusion. Flow cytometry analysis of bone marrow (left panels), spleen (middle panels) and liver
(right panels) from splenectomized (top panels), non splenectomized (middle panels), and nontransfused controls (bottom panels) of
representative mice are shown. The small numbers indicate the frequency of the cells detected within the respective quadrant. Values
within circles correspond to the percentage of human cells calculated by subtracting the frequency detected in the negative controls in
the corresponding bottom panels. The red circles indicate the frequency of human cells. Of note, the majority of the human CD235a positive
cells were negative for CD36, an indication that the human EBs had matured in vivo. Similar results were obtained by analyzing the cells for
eGFP expression. Data are representative of those obtained with 3 mice per experimental point.
of human type O+ red cells, as ﬁrst reported by Neildez-
Nguyen et al. [7]. However, since Chaurasia et al. [32] did
not measure the levels of adhesion receptors expressed by
VPA-treated EBs, it is not possible to assess the relative
contribution of functional splenectomy and/or upregulation
of CXCR4 (and/or down regulation of VLA-4 and PSGL-1
expression) to the improved lodgment of these cells in the
marrow. Further studies are necessary to clarify this issue
in order to establish the optimal pre-treatment (splenec-
tomy versus functional reticulo-endotheium blockade) of
the mouse model for functional evaluation of transfusion
products generated by diﬀerent stem cell sources.
Am a j o rd i ﬀerence between this study and the report by
Chaurasia et al. [32] is represented by the levels of human
erythrocytes detected in the blood of the transfused animals.
In our study, human erythrocytes were barely detectable
in the blood at any time point after transfusion while in
the study of Chaurasia et al. discrete numbers of mature
erythrocytes were detectable in the circulation starting
from day 7 after transfusion (15% in NOD/SCID mice
and 30% in the improved NOD/SCID/IL2Rγnull model).
H o w e v e r ,p r o g e n i t o rc e l l sw e r en ol o n g e rd e t e c t a b l ea m o n g
the human EBs expanded under HEMA conditions in this
study (CD45pos cells were undetected in the transfused mice)12 Stem Cells International
while representing a signiﬁcant proportion (7%) of the VPA-
treated cells transfused by Chaurasia et al. [32]. It is therefore
possible that in this case release of human erythrocytes in the
blood was favored by the presence of human macrophages
generated by human hematopoietic progenitors in the
animal model. Another possibility, however, is that in our
experiments, the erythrocytes released in the blood were
cleared by the immune system.
Immunological responses have represented a barrier to
the development of mouse models for functional assessment
of human red cell products [33]. These barriers include
cell-mediated and humoral immune responses triggered by
antigens speciﬁcally expressed on red cells. Since some of the
epitopes present on red cell antigens are expressed also by
proteins on the membrane of bacteria presents in gut ﬂora
[34], red blood cells may trigger immune reactions leading
to red cell lyses even in the absence of any prior sensitization.
NOD/SCID, and the improved NOD/SCID/IL2Rγnull mice,
lack cell mediated and immunoglobulin-mediated humoral
responses (these mice do not have B cells). In addition,
a great proportion of the immune-response against red
blood cell antigens are often initiated in the spleen [35]
which was transiently inactivated in [7, 32] and permanently
removed in our study. The complement system plays a
signiﬁcant role in the humoral mediated red cell clearance
in vivo. Since NOD/SCID/IL2Rγnull mice lack C5 [21], they
have reduced activation levels of the alternative complement
pathway. However, these mice express C3 [21]a n dm a y
activate the classical complement pathway responsible for
lysis of the human CD55 and CD59 deﬁcient red cells
observed in paroxysmal nocturnal hemoglobinuria (PNH)
[36], preventing the use of NOD/SCID/IL2Rγnull mice for
development of animal models for PNH studies. Human
CB EBs expanded ex vivo under HEMA conditions express
CD55 (53–87% positive EBs, MFI = 110–330) and CD49
(54–70%, MFI = 1,900–2500). However, the expression of
these antigens greatly decreased when the cells were induced
to mature with EPO for 5 days ex vivo (CD55: 17–27% EBs,
MFI = 30–32; CD59: 28–56%, MFI = 20–76, data from 2
separate cultures) (A.R.Migliaccio and C.Whitsett, unpub-
lished data). It is therefore possible that ex vivo expanded
human EBs also lost CD55/CD59 expression during their
maturation in the marrow of NOD/SCID/IL2Rγnull mice
making their progeny susceptible to C3-mediated lysis. Since
C3 deﬁcient mice have been recently developed [37], we
predict that C3-deﬁcient NOD/SCID/IL2Rγnull mice will
represent a better read-out animal model for the presence of
human erythrocytes in the blood.
In conclusion, we describe data indicating that splenec-
tomized NOD/SCID/IL2Rγnull mice represent a surrogate in
vivo model to assess the potency of transfusion products
generated ex vivo from diﬀerent stem cell sources.
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